To evaluate the extent to which these cross-regulatory interactions could control cancer splicing programs, we analyzed the proportion of splicing factors in each class—oncogenic-like, tumor suppressor-like, and non-driver-like—regulated by another splicing factor class. The gene discussed is SLU7; the disease is neoplasm.